KR20130042601A - 항―ｖｅｇｆｒ―３ 항체 조성물 - Google Patents

항―ｖｅｇｆｒ―３ 항체 조성물 Download PDF

Info

Publication number
KR20130042601A
KR20130042601A KR1020137005794A KR20137005794A KR20130042601A KR 20130042601 A KR20130042601 A KR 20130042601A KR 1020137005794 A KR1020137005794 A KR 1020137005794A KR 20137005794 A KR20137005794 A KR 20137005794A KR 20130042601 A KR20130042601 A KR 20130042601A
Authority
KR
South Korea
Prior art keywords
leu
ser
val
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137005794A
Other languages
English (en)
Korean (ko)
Inventor
브로니슬로 파이토우스키
크리쉬나다트 페르사우드
나탈리 자예크
Original Assignee
임클론 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130042601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 임클론 엘엘씨 filed Critical 임클론 엘엘씨
Publication of KR20130042601A publication Critical patent/KR20130042601A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020137005794A 2010-09-07 2011-09-01 항―ｖｅｇｆｒ―３ 항체 조성물 Ceased KR20130042601A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07
US61/380,432 2010-09-07
PCT/US2011/050131 WO2012033696A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Publications (1)

Publication Number Publication Date
KR20130042601A true KR20130042601A (ko) 2013-04-26

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137005794A Ceased KR20130042601A (ko) 2010-09-07 2011-09-01 항―ｖｅｇｆｒ―３ 항체 조성물

Country Status (26)

Country Link
US (2) US8481034B2 (enExample)
EP (1) EP2614081B1 (enExample)
JP (1) JP2013538813A (enExample)
KR (1) KR20130042601A (enExample)
CN (1) CN103080133A (enExample)
AR (1) AR082641A1 (enExample)
AU (1) AU2011299443B2 (enExample)
BR (1) BR112013005423A2 (enExample)
CA (1) CA2809375C (enExample)
CL (1) CL2013000607A1 (enExample)
CO (1) CO6690754A2 (enExample)
CR (1) CR20130065A (enExample)
DO (1) DOP2013000039A (enExample)
EA (1) EA023331B1 (enExample)
EC (1) ECSP13012481A (enExample)
ES (1) ES2568801T3 (enExample)
GT (1) GT201300058A (enExample)
MA (1) MA34487B1 (enExample)
MX (1) MX2013002718A (enExample)
PE (1) PE20131328A1 (enExample)
PH (1) PH12013500432A1 (enExample)
SG (1) SG188265A1 (enExample)
TW (1) TWI413527B (enExample)
UA (1) UA109148C2 (enExample)
WO (1) WO2012033696A1 (enExample)
ZA (1) ZA201300804B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064203A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
EP3244924B1 (en) * 2015-01-15 2021-04-07 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets
CA3044682A1 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002248372B8 (en) * 2001-01-19 2008-03-20 Vegenics Limited FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CN101277976B (zh) 2005-10-06 2012-04-11 伊莱利利公司 抗肌抑制素抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물

Also Published As

Publication number Publication date
EA023331B1 (ru) 2016-05-31
CN103080133A (zh) 2013-05-01
ZA201300804B (en) 2014-07-30
DOP2013000039A (es) 2013-04-15
CO6690754A2 (es) 2013-06-17
AU2011299443A1 (en) 2013-02-14
PE20131328A1 (es) 2013-11-18
TWI413527B (zh) 2013-11-01
US8784818B2 (en) 2014-07-22
ECSP13012481A (es) 2015-03-31
SG188265A1 (en) 2013-04-30
EA201390117A1 (ru) 2013-06-28
TW201223543A (en) 2012-06-16
MA34487B1 (fr) 2013-08-01
US8481034B2 (en) 2013-07-09
CR20130065A (es) 2013-03-21
BR112013005423A2 (pt) 2016-06-07
CA2809375A1 (en) 2012-03-15
EP2614081B1 (en) 2016-03-16
WO2012033696A1 (en) 2012-03-15
GT201300058A (es) 2014-07-16
CA2809375C (en) 2016-02-09
AR082641A1 (es) 2012-12-19
US20130280278A1 (en) 2013-10-24
US20120058126A1 (en) 2012-03-08
UA109148C2 (uk) 2015-07-27
AU2011299443B2 (en) 2014-06-05
PH12013500432A1 (en) 2017-08-23
EP2614081A1 (en) 2013-07-17
MX2013002718A (es) 2013-05-01
CL2013000607A1 (es) 2014-04-11
JP2013538813A (ja) 2013-10-17
ES2568801T3 (es) 2016-05-04

Similar Documents

Publication Publication Date Title
AU2015292374B2 (en) Bispecific HER2 and CD3 binding molecules
RU2734076C2 (ru) Антитела, направленные на cd127
CN101027322B (zh) 促红细胞生成素受体结合抗体
JP6533534B2 (ja) 膠芽腫の治療に使用するための組成物及びその使用
US20090226442A1 (en) RON antibodies and uses thereof
CN103524618A (zh) 促红细胞生成素受体结合抗体
KR20090114388A (ko) 질환 특이적 결합 분자 및 표적을 제공하는 방법
KR20130135872A (ko) 중화 항-ccl20 항체
KR20110074612A (ko) ｃ-ＭＥＴ 항체
US11046768B2 (en) Bispecific HER2 and CD3 binding molecules
KR20180086295A (ko) 온코스타틴 m 수용체 항원 결합 단백질
AU2011299443B2 (en) Anti-VEGFR-3 antibody compositions
JP2010535763A (ja) 抗ｒａｎｔｅｓ抗体およびその使用の方法
US20190359732A1 (en) Bispecific her2 and cd3 binding molecules
CA3051484A1 (en) Bispecific her2 and cd3 binding molecules
CN114685658B (zh) Ox40的靶向抗体及其制备方法和应用
JP2021504492A (ja) 癌治療のための組成物および方法

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
PA0105 International application

Patent event date: 20130306

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130306

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140929

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150424

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140929

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20150424

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20141128

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130306

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20150626

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150526

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20150424

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141128

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140929

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130306

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20150923

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20150626

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20150424

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2015101005542

Request date: 20150923

J301 Trial decision

Free format text: TRIAL NUMBER: 2015101005542; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20150923

Effective date: 20170220

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20170220

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20150923

Decision date: 20170220

Appeal identifier: 2015101005542